

# David R Ferry

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11184105/david-r-ferry-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26  
papers

4,289  
citations

23  
h-index

26  
g-index

26  
ext. papers

4,631  
ext. citations

7.8  
avg, IF

4.29  
L-index

#	Paper	IF	Citations
26	Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 77-86	3.5	9
25	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2279-2287	2.2	74
24	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2014</b> , 383, 31-39	40	1475
23	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 894-904	21.7	213
22	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluorouracil-based chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1845-1855	2.2	10
21	Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3505-3505	2.2	9
20	Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. <i>International Journal of Oncology</i> , <b>2009</b> , 34, 1629-36	1	218
19	A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5869-75	12.9	109
18	Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. <i>Lancet, The</i> , <b>2007</b> , 370, 143-152 <sup>40</sup>	40	446
17	Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1668-76	2.2	349
16	The genetic basis of resistance to cancer chemotherapy. <i>Annals of Medicine</i> , <b>1995</b> , 27, 157-67	1.5	26
15	Resolving the structure of the Ca <sup>2+</sup> channel by photoaffinity labelling. <i>Trends in Pharmacological Sciences</i> , <b>1987</b> , 8, 95-100	13.2	57
14	Stereoselective photoaffinity labelling of the purified 1,4-dihydropyridine receptor of the voltage-dependent calcium channel. <i>FEBS Journal</i> , <b>1986</b> , 161, 603-9		82
13	Assay for calcium channels. <i>Methods in Enzymology</i> , <b>1985</b> , 109, 513-50	1.7	166
12	(-)-3H-desmethoxyverapamil labelling of putative calcium channels in brain: autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1984</b> , 327, 183-7	3.4	79
11	125I-iodipine, a new high affinity ligand for the putative calcium channel. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1984</b> , 325, 186-9	3.4	23
10	Novel 1,4-dihydropyridine (Bay K 8644) facilitates calcium-dependent [3H]noradrenaline release from PC 12 cells. <i>Journal of Neurochemistry</i> , <b>1984</b> , 42, 1186-9	6	56

9	Target size analysis and molecular properties of Ca <sup>2+</sup> channels labelled with [3H]verapamil. <i>FEBS Journal</i> , <b>1984</b> , 141, 177-86		51
8	Photoaffinity labelling of Ca <sup>2+</sup> channels with [3H]azidopine. <i>FEBS Letters</i> , <b>1984</b> , 169, 112-8	3.8	81
7	Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with 3H-nimodipine radioligand binding. <i>Journal of Receptors and Signal Transduction</i> , <b>1983</b> , 3, 177-90		47
6	Differential labelling of putative skeletal muscle calcium channels by [3H]-nifedipine, [3H]-nitrendipine, [3H]-nimodipine and [3H]-PN 200 110. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1983</b> , 323, 276-7	3.4	50
5	Purification of the putative calcium channel from skeletal muscle with the aid of [3H]-nimodipine binding. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1983</b> , 323, 1-11	3.4	87
4	Solubilization and partial purification of putative calcium channels labelled with [3H]-nimodipine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1983</b> , 323, 279-91	3.4	93
3	Calcium channels: direct identification with radioligand binding studies. <i>Trends in Pharmacological Sciences</i> , <b>1982</b> , 3, 431-437	13.2	273
2	Identification of putative calcium channels in skeletal muscle microsomes. <i>FEBS Letters</i> , <b>1982</b> , 148, 331-7, 8		95
1	Evidence of multiple receptor sites within the putative calcium channel. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1982</b> , 321, 80-3	3.4	111